Curcumin in the Treatment of Kidney Disease: A Systematic Review with a Focus on Drug Interactions
Open Access
- 18 November 2025
- journal article
- review article
- Published by MDPI AG in Antioxidants
- Vol. 14 (11) , 1369
Abstract
Kidney disease (KD) is a major health challenge, affecting millions of people worldwide, highlighting the need for improved prevention and management strategies. The pathophysiological mechanisms converged on a common pathway characterized by inflammation, oxidative stress, fibrosis, nephron loss and failure. Curcumin, the active compound derived from turmeric (Curcuma longa), attracts considerable interest as a potential therapy for KD due to its anti-inflammatory, antioxidant and anti-fibrotic properties. Despite the benefits of curcumin, co-administration with kidney medications may cause drug interactions. Here, we systematically reviewed the efficacy of curcumin in alleviating KD and its safety when used with conventional treatments. Search terms included: curcumin AND (“diabetic nephropathy” OR “renal disease” OR “kidney disease”). Data on mechanisms of action, redox status, clinical benefits, side effects, and drug interactions were extracted and analyzed. Curcumin reduces oxidative stress, inflammation, apoptosis, fibrosis, ER stress, and lipid and glucose metabolism. Curcumin has multifaceted nephroprotective effects, while it is safe and well-tolerated. The curcumin–drug interactions reviewed were: -piperine, -epigallocatechin gallate, -losartan, -ginkgolide B, -rosuvastatin, -insulin, -cilostazol, and -ginger. These interactions improve curcumin bioavailability, and synergistic anti-inflammatory/antioxidant/antifibrotic and renoprotective effects. Future research should prioritize large-scale clinical trials to evaluate the efficacy and safety of curcumin in diverse KD populations.Keywords
Funding Information
- ANID-FONDECYT-Iniciación (11230112)
- Vicerrectoría de Investigación, Creación Artística y Doctorado de la Universidad Finis Terrae
This publication has 96 references indexed in Scilit:
- Preclinical pharmacology and pharmacokinetics of curcumin tagged cilostazol nanodispersion for the management of diabetic nephropathy in wister rat modelIn Silico Pharmacology, 2024
- Tetrahydrocurcumin Add‐On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injuryPharmacology Research & Perspectives, 2023
- The Use of Curcumin for the Treatment of Renal Disorders: A Systematic Review of Randomized Controlled Trials2021
- Curcumin Improves Biomolecules Associated with Renal Function and Attenuates Oxidative Injury and Histopathological Changes in Potassium-Induced Toxicity in Rats’ KidneyBiological Trace Element Research, 2020
- Prevalence and Disease Burden of Chronic Kidney Disease2019
- Review of herbal medications with the potential to cause bleeding: dental implications, and risk prediction and prevention avenuesEPMA Journal, 2019
- Piperine Decreases Binding of Drugs to Human Plasma and Increases Uptake by Brain Microvascular Endothelial CellsPhytotherapy Research, 2017
- Evaluation of the Effect of Curcumin Capsules on Glyburide Therapy in Patients with Type‐2 Diabetes MellitusPhytotherapy Research, 2014
- Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)‐κB and NF‐κB‐regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesisMolecular Nutrition & Food Research, 2011
- Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney diseaseCochrane Database of Systematic Reviews, 2006